Longitudinal Characterization of Autoantibodies to the Thyrotropin Receptor (TRAb) During Alemtuzumab Therapy: Evidence that TRAb May Precede Thyroid Dysfunction by Many Years-Reference-Cited by-同舟云学术

Longitudinal Characterization of Autoantibodies to the Thyrotropin Receptor (TRAb) During Alemtuzumab Therapy: Evidence that TRAb May Precede Thyroid Dysfunction by Many Years

Published:2018-12 Issue:12 Volume:28 Page:1682-1693
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Muller Ilaria¹,Willis Mark²,Healy Sarah²,Nasser Taha²,Loveless Samantha²,Butterworth Sara²,Zhang Lei¹,Draman Mohd S.¹,Taylor Peter N.¹,Robertson Neil²,Dayan Colin M.¹,Ludgate Marian E.¹

Affiliation:

1. Thyroid Research Group, Division of Infection and Immunity, School of Medicine; School of Medicine; Cardiff University, University Hospital of Wales, Cardiff, United Kingdom.

2. Division of Psychological Medicine and Clinical Neurosciences, School of Medicine; Cardiff University, University Hospital of Wales, Cardiff, United Kingdom.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2018.0232

Reference38 articles.

1. Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

2. B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis

3. The window of therapeutic opportunity in multiple sclerosis

4. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

5. Immune competence after alemtuzumab treatment of multiple sclerosis

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring autoimmune endocrine diseases induced by monoclonal antibodies used as multiple sclerosis pharmacotherapy: a systematic review;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-09-09

2. Alemtuzumab-induced thyroid disease: a Danish cohort study;Multiple Sclerosis and Related Disorders;2024-09

3. Risk of secondary autoimmune diseases with alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis;Frontiers in Immunology;2024-04-16

4. Alemtuzumab-induced thyroid eye disease successfully treated with a single low-dose of rituximab;European Thyroid Journal;2024-03

5. Alemtuzumab induces severe orbitopathy in relapsing–remitting multiple sclerosis;Journal of Neurology;2023-09-29